120 results on '"Leineweber K"'
Search Results
2. ADTRP regulates TFPI expression via transcription factor POU1F1 involved in coronary artery disease
- Author
-
Luo, C., Pook, E., Wang, F., Archacki, S.R., Tang, B., Zhang, W., Hu, J.-S., Yang, J., Leineweber, K., Bechem, M., Huang, W., Song, Y., Cheung, S.-H., Laux, V., Ke, T., Ren, X., Tu, X., Chen, Q., Wang, Q.K., Xu, C., and Publica
- Abstract
Genomic variants in both ADTRP and TFPI genes are associated with risk of coronary artery disease (CAD). ADTRP regulates TFPI expression and endothelial cell functions involved in the initiation of atherosclerotic CAD. ADTRP also specifies primitive myelopoiesis and definitive hematopoiesis by upregulating TFPI expression. However, the underlying molecular mechanism is unknown. Here we show that transcription factor POU1F1 is the key by which ADTRP regulates TFPI expression. Luciferase reporter assays, chromatin-immunoprecipitation (ChIP) and electrophoretic mobility shift assay (EMSA) in combination with analysis of large and small deletions of the TFPI promoter/regulatory region were used to identify the molecular mechanism by which ADTRP regulates TFPI expression. Genetic association was assessed using case-control association analysis and phenome-wide association analysis (PhenGWA). ADTRP regulates TFPI expression at the transcription level in a dose-dependent manner. The ADTRP-response element was localized to a 50 bp region between −806 bp and −756 bp upstream of TFPI transcription start site, which contains a binding site for POU1F1. Deletion of POU1F1-binding site or knockdown of POU1F1 expression abolished ADTRP-mediated transcription of TFPI. ChIP and EMSA demonstrated that POU1F1 binds to the ADTRP response element. Genetic analysis identified significant association between POU1F1 variants and risk of CAD. PhenGWA identified other phenotypic traits associated with the ADTRP-POU1F1-TFPI axis such as lymphocyte count (ADTRP), waist circumference (TFPI), and standing height (POU1F1). These data identify POU1F1 as a transcription factor that regulates TFPI transcription in response to ADTRP, and link POU1F1 variants to risk of CAD for the first time.
- Published
- 2020
3. Coronary microembolization
- Author
-
Skyschally, A., Leineweber, K., Gres, P., Haude, M., Erbel, R., and Heusch, G.
- Published
- 2006
- Full Text
- View/download PDF
4. β-Adrenoceptor polymorphisms
- Author
-
Leineweber, K., Büscher, R., Bruck, H., and Brodde, O.-E.
- Published
- 2004
- Full Text
- View/download PDF
5. Genetic interactions in the β-adrenoceptor/G-protein signal transduction pathway and survival after coronary artery bypass grafting: a pilot study†
- Author
-
Frey, U. H., Kottenberg, E., Kamler, M., Leineweber, K., Manthey, I., Heusch, G., Siffert, W., and Peters, J.
- Published
- 2011
- Full Text
- View/download PDF
6. Beta-1− and Beta-2-adrenoceptor polymorphisms and cardiovascular diseases: S10.2
- Author
-
Leineweber, K and Heusch, G
- Published
- 2008
7. Presynaptic α-2C Adrenoceptor-mediated Control of Noradrenaline Release in Humans: Genotype- or Age-Dependent?
- Author
-
Bruck, H, Schwerdtfeger, T, Toliat, M, Leineweber, K, Heusch, G, Philipp, T, Nürnberg, P, and Brodde, O-E
- Published
- 2007
- Full Text
- View/download PDF
8. Is cyclic AMP formation desensitized in patients with end-stage renal failure?
- Author
-
Leineweber, K., Schwiebert, C., Büscher, R., and Michel, M. C.
- Published
- 2005
9. β2-Adrenoceptor polymorphisms and desensitization of cardiac responses
- Author
-
Brodde, O.-E. and Leineweber, K.
- Published
- 2003
10. A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism project (GMP-VTE)
- Author
-
Ten Cate, V., primary, Koeck, T., additional, Panova-Noeva, M., additional, Rapp, S., additional, Prochaska, J.H., additional, Lenz, M., additional, Schulz, A., additional, Eggebrecht, L., additional, Hermanns, M.I., additional, Heitmeier, S., additional, Krahn, T., additional, Laux, V., additional, Münzel, T., additional, Leineweber, K., additional, Konstantinides, S.V., additional, and Wild, P.S., additional
- Published
- 2019
- Full Text
- View/download PDF
11. Central sensitisation and activation of serotonin uptake in patients with medication overuse headache
- Author
-
Ayzenberg, I, Katsarava, Z, Leineweber, K, Franke, L, Limmroth, V, Kaube, H, and Diener, H.C
- Published
- 2024
- Full Text
- View/download PDF
12. Der Arg389Gly Beta1-Adrenozeptor Polymorphismus beeinflußt die Katecholamin-stimulierte Plasma-Renin-Aktivität
- Author
-
Bruck, H, Leineweber, K, Temme, T, Brodde, O-E, and Philipp, T
- Subjects
ddc: 610 - Published
- 2006
13. Einfluß der Gln27Glu- und Arg16Gly-Beta2-Adrenozeptor Polymorphismen auf die Agonist-induzierte Desensibilisierung der beta2-Adrenozeptor vermittelten Venendilatation in vivo
- Author
-
Bruck, H, Park, J, Leineweber, K, Brodde, OE, and Philipp, T
- Subjects
ddc: 610 - Published
- 2005
14. T-04-08: Platelet responsiveness in the post-acute phase of pulmonary embolism.
- Author
-
von Ungern-Sternberg, S., ten Cate, V., Panova-Noeva, M., Dahlen, B., Prochaska, J. H., Heitmeier, S., Gerdes, C., Konstantinides, S. V., Münzel, T., Espinola-Klein, C., Lackner, K. J., ten Cate, H., Leineweber, K., Wild, P. S., and Jurk, K.
- Published
- 2023
- Full Text
- View/download PDF
15. Arg389Gly beta1-adrenoceptor polymorphism determines catecholamine effects on plasma-renin-activity
- Author
-
Bruck, H, Leineweber, K, Temme, T, Brodde, O-E, Philipp, T, Bruck, H, Leineweber, K, Temme, T, Brodde, O-E, and Philipp, T
- Published
- 2006
16. Effects of the Gln27Glu- and the Arg16Gly-beta2-adrenoceptor polymorphisms on agonist-induced desensitization of beta2-adrenoceptor-mediated venodilation in vivo
- Author
-
Bruck, H, Park, J, Leineweber, K, Brodde, OE, Philipp, T, Bruck, H, Park, J, Leineweber, K, Brodde, OE, and Philipp, T
- Published
- 2005
17. Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function
- Author
-
Baumann, M., primary, Leineweber, K., additional, Tewiele, M., additional, Wu, K., additional, Turk, T. R., additional, Su, S., additional, Gossl, M., additional, Buck, T., additional, Wilde, B., additional, Heemann, U., additional, Kribben, A., additional, and Witzke, O., additional
- Published
- 2010
- Full Text
- View/download PDF
18. Methoden zur Messung der Azetylsalizylsäure- bzw. Clopidogrelresistenz
- Author
-
Adamzik, M., primary, Bachmann, H. S., primary, Görlinger, K., primary, Grandoch, M., primary, Leineweber, K., primary, Müller-Beißenhirtz, H., primary, Wenzel, F., primary, Naber, C., primary, and Weber, A.-A., additional
- Published
- 2008
- Full Text
- View/download PDF
19. Dynamic transitions in the translocated phloem filament protein
- Author
-
Leineweber, K., Schulz, A., Thompson, G. A., Leineweber, K., Schulz, A., and Thompson, G. A.
- Published
- 2000
20. Limitations of two TCA's serotonergic effects on visceral nociception in a rat model
- Author
-
Bechmann, L, primary, Best, J, additional, Leineweber, K, additional, Holtmann, G, additional, and Gerken, G, additional
- Published
- 2007
- Full Text
- View/download PDF
21. Tricyclic antidepressant's effects on visceral nociception and its underlying mechanisms
- Author
-
Bechmann, L, primary, Best, J, additional, Leineweber, K, additional, Holtmann, G, additional, and Gerken, G, additional
- Published
- 2006
- Full Text
- View/download PDF
22. 416 The Thr164Ile-beta2-adrenoceptor and heart failure
- Author
-
LEINEWEBER, K, primary, BRODDE, O, additional, HEUSCH, G, additional, and KOERFER, R, additional
- Published
- 2006
- Full Text
- View/download PDF
23. Central sensitisation and activation of serotonin uptake in patients with medication overuse headache
- Author
-
Ayzenberg, I, primary, Katsarava, Z, additional, Leineweber, K, additional, Franke, L, additional, Limmroth, V, additional, Kaube, H, additional, and Diener, H.C, additional
- Published
- 2005
- Full Text
- View/download PDF
24. Human β-adrenergic receptor gene haplotypes and venodilation in vivo
- Author
-
BRUCK, H, primary, LEINEWEBER, K, additional, PARK, J, additional, WEBER, M, additional, HEUSCH, G, additional, PHILIPP, T, additional, and BRODDE, O, additional
- Published
- 2005
- Full Text
- View/download PDF
25. �-Adrenoceptor polymorphisms
- Author
-
Leineweber, K., primary, B�scher, R., additional, Bruck, H., additional, and Brodde, O.-E., additional
- Published
- 2004
- Full Text
- View/download PDF
26. 179 The Thr164Ile polymorphism of the human beta-2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo
- Author
-
BRUCK, H, primary, LEINEWEBER, K, additional, BEILFUS, A, additional, and BRODDE, O, additional
- Published
- 2003
- Full Text
- View/download PDF
27. Methoden zur Messung der Azetylsalizylsäure- bzw. Clopidogrelresistenz
- Author
-
Weber, A.-A., Adamzik, M., Bachmann, H. S., Görlinger, K., Grandoch, M., Leineweber, K., Müller-Beißenhirtz, H., Wenzel, F., and Naber, C.
- Published
- 2008
- Full Text
- View/download PDF
28. Cyclic adenosine monophosphate in acute myocardial infarction with heart failure: slayer or savior?
- Author
-
Leineweber K, Böhm M, and Heusch G
- Published
- 2006
29. Protein expression profiling suggests relevance of non-canonical pathways in isolated pulmonary embolism
- Author
-
Ten Cate, V, Prochaska, JH, Schulz, A, Koeck, T, Pallares Robles, A, Lenz, M, Eggebrecht, L, Rapp, S, Panova-Noeva, M, Ghofrani, HA, Meyer, FJ, Espinola-Klein, C, Lackner, KJ, Michal, M, Schuster, AK, Strauch, K, Zink, AM, Laux, V, Heitmeier, S, Konstantinides, SV, Münzel, T, Andrade-Navarro, MA, Leineweber, K, and Wild, PS
- Abstract
Patients with isolated pulmonary embolism (PE) have a distinct clinical profile from those with deep vein thrombosis (DVT)-associated PE, with more pulmonary conditions and atherosclerosis. These findings suggest a distinct molecular pathophysiology and the potential involvement of alternative pathways in isolated PE. To test this hypothesis, data from 532 individuals from the Genotyping and Molecular Phenotyping of Venous ThromboEmbolism (GMP-VTE) Project, a multi-center prospective cohort study with extensive biobanking, were analyzed. Targeted, high-throughput proteomics, machine learning, and bioinformatic methods were applied to contrast the acute-phase plasma proteomes of isolated PE patients (n=96) against those of patients with DVT-associated PE (n=276) or isolated DVT (n=160). This resulted in the identification of shared molecular processes between PE phenotypes, as well as an isolated PE-specific protein signature. Shared processes included upregulation of inflammation, response to oxidative stress, and the loss of pulmonary surfactant. The isolated PE-specific signature consisted of five proteins: interferon-γ (IFNG), glial cell line-derived neurotrophic growth factor (GDNF), polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3), peptidyl arginine deiminase type-2 (PADI2) and interleukin-15 receptor subunit α (IL-15Rα). These proteins were orthogonally validated using cisprotein quantitative trait loci (cispQTLs). External replication in an independent population-based cohort (n=5,778) further validated the proteomic results, and showed that they were prognostic for incident primary isolated PE in individuals without history of VTE (median time to event: 2.9 years, interquartile range: 1.6 - 4.2 years), supporting their possible involvement in the early pathogenesis. This study has identified molecular overlaps and differences between VTE phenotypes. In particular, the results implicate non-canonical pathways more commonly associated with respiratory and atherosclerotic disease in the acute pathophysiology of isolated PE.
- Published
- 2021
- Full Text
- View/download PDF
30. 179 The Thr164Ile polymorphism of the human beta-2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo
- Author
-
Bruck, H., Leineweber, K., Beilfuß, A., and Brodde, O.-E.
- Subjects
- *
BETA adrenoceptors , *DESENSITIZATION (Psychotherapy) - Abstract
An abstract of the article "The Thr164Ile Polymorphism of the Human Beta-2-Adrenoceptor Exhibits Blunted Desensitization of Cardiac Functional Responses in Vivo," by H. Bruck and colleagues is presented.
- Published
- 2004
31. Unsupervised clustering of venous thromboembolism patients by clinical features at presentation identifies novel endotypes that improve prognostic stratification.
- Author
-
Pallares Robles A, Ten Cate V, Lenz M, Schulz A, Prochaska JH, Rapp S, Koeck T, Leineweber K, Heitmeier S, Opitz CF, Held M, Espinola-Klein C, Lackner KJ, Münzel T, Konstantinides SV, Ten Cate-Hoek A, Ten Cate H, and Wild PS
- Subjects
- Female, Humans, Cluster Analysis, Prognosis, Proteomics, Risk Factors, Male, Venous Thromboembolism drug therapy
- Abstract
Background: Individuals with acute venous thromboembolism (VTE) constitute a heterogeneous group of patients with diverse clinical characteristics and outcome., Objectives: To identify endotypes of individuals with acute VTE based on clinical characteristics at presentation through unsupervised cluster analysis and to evaluate their molecular proteomic profile and clinical outcome., Methods: Data from 591 individuals from the Genotyping and Molecular phenotyping of Venous thromboembolism (GMP-VTE) project were explored. Hierarchical clustering was applied to 58 variables to define VTE endotypes. Clinical characteristics, three-year incidence of thromboembolic events or death, and acute-phase plasma proteomics were assessed., Results: Four endotypes were identified, exhibiting different patterns of clinical characteristics and clinical course. Endotype 1 (n = 300), comprising older individuals with comorbidities, had the highest incidence of thromboembolic events or death (HR [95 % CI]: 3.76 [1.96-7.19]), followed by endotype 4 (n = 127) (HR [95 % CI]: 2.55 [1.26-5.16]), characterised by men with history of VTE and provoking risk factors, and endotype 3 (n = 57) (HR [95 % CI]: 1.57 [0.63-3.87]), composed of young women with provoking risk factors, vs. reference endotype 2 (n = 107). The reference endotype was constituted by individuals diagnosed with PE without comorbidities, who had the lowest incidence of the investigated endpoint. Differentially expressed proteins associated with the endotypes were related to distinct biological processes, supporting differences in molecular pathophysiology. The endotypes had superior prognostic ability compared to existing risk stratifications such as provoked vs unprovoked VTE and D-dimer levels., Conclusion: Four endotypes of VTE were identified by unsupervised phenotype-based clustering that diverge in clinical outcome and plasmatic protein signature. This approach might support the future development of individualized treatment in VTE., Competing Interests: Declaration of competing interest P.S.W. has received research funding outside the present study from Boehringer Ingelheim, Sanofi-Aventis, Bayer Healthcare, Daiichi Sankyo Europe and Novartis and received outside the present study honoraria for lectures or consulting from Boehringer Ingelheim, Bayer HealthCare, Evonik, AstraZeneca and Sanofi Aventis. P.S.W. is principal investigator of the DIASyM research core (BMBF 161L0217A). SH and KL are employees of Bayer AG. H.T.C. received research funding outside the present study from Bayer and received outside the present study honoraria for consultation and/or advisory board participation, from Bayer, Alveron, Galapagos, Portola and Alexion. All reimbursements were transferred to the CARIM institute. HtC is a shareholder with Coagulation Profile, a university spinoff small diagnostic company not involved in the present study., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
32. Subtype-specific plasma signatures of platelet-related protein releasate in acute pulmonary embolism.
- Author
-
Baidildinova G, Ten Cate V, Nagler M, Panova-Noeva M, Rapp S, Köck T, Prochaska JH, Heitmeier S, Gerdes C, Schwers S, Konstantinides SV, Münzel T, Espinola-Klein C, Lackner KJ, Spronk HMN, Ten Cate H, van der Meijden PEJ, Leineweber K, Wild PS, and Jurk K
- Subjects
- Humans, Prospective Studies, Blood Platelets, Acute Disease, Risk Factors, Venous Thromboembolism complications, Pulmonary Embolism complications
- Abstract
Introduction: There is evidence that plasma protein profiles differ in the two subtypes of pulmonary embolism (PE), isolated PE (iPE) and deep vein thrombosis (DVT)-associated PE (DVT-PE), in the acute phase. The aim of this study was to determine specific plasma signatures for proteins related to platelets in acute iPE and DVT-PE compared to isolated DVT (iDVT)., Methods: Within the Genotyping and Molecular Phenotyping of Venous ThromboEmbolism (GMP-VTE) Project, a multicenter prospective cohort study of 693 confirmed VTE cases, a highly sensitive targeted proteomics approach based on dual-antibody proximity extension assay was applied. LASSO-regularized logistic regression analysis selected 33 and 30 of 135 platelet-related candidate proteins in iPE and DVT-PE vs. iDVT, respectively., Results: All regulated proteins were well associated with six prominently released platelet proteins and the majority showed specificity for iPE and DVT-PE compared to iDVT. While iPE-specific proteins were assigned to be predominantly released via shedding mechanisms and extracellular vesicles, granule secretion was identified as a major release mechanism assigned to DVT-associated PE-specific proteins. Network analysis demonstrated three interconnected clusters of specifically regulated proteins in iPE linked to immunoreceptor signaling, pathogen clearance and chemotaxis, whereas for DVT-associated PE one cluster linked to tissue remodeling and leukocyte trafficking. Machine learning-based analysis reveals specific plasma signatures and differential release mechanisms of proteins related to platelets in acute iPE and DVT-associated PE., Conclusion: These data suggest that the platelet protein releasate contributes to the differential regulation of plasma proteins in acute PE compared to iDVT, which may be associated with different platelet activation patterns., Competing Interests: Declaration of competing interest S.H., C.G., S.S., and K.L. are employees of Bayer AG. The study was sponsored inter alia by Bayer AG. The sponsors had no role in the design or conduct of the research. H.T.C. received research funding outside the present study from Bayer and received outside the present study honoraria for consultation and/or advisory board participation, from Bayer, Alveron, Galapagos, Portola and Alexion. All reimbursements were transferred to the CARIM institute. H.T.C. and H.M.H.S. are shareholders with Coagulation Profile, a university spinoff small diagnostic company not involved in the present study. P.S.W. has received research funding outside the present study from Boehringer Ingelheim, Sanofi-Aventis, Bayer Healthcare, Daiichi Sankyo Europe and Novartis and received outside the present study honoraria for lectures or consulting from Boehringer Ingelheim, Bayer HealthCare, Evonik, AstraZeneca and Sanofi-Aventis. P.S.W. is principal investigator of the DIASyM research core (BMBF 161L0217A)., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis.
- Author
-
Pallares Robles A, Ten Cate V, Schulz A, Prochaska JH, Rapp S, Koeck T, Panova-Noeva M, Heitmeier S, Schwers S, Leineweber K, Seyfarth HJ, Opitz CF, Spronk H, Espinola-Klein C, Lackner KJ, Münzel T, Andrade-Navarro MA, Konstantinides SV, Ten Cate H, and Wild PS
- Subjects
- Animals, Apoptosis, Extracellular Matrix, Factor XIa, Humans, Inflammation, Lipid Metabolism, Mice, Venous Thromboembolism, Venous Thrombosis drug therapy
- Abstract
Animal experiments and early phase human trials suggest that inhibition of factor XIa (FXIa) safely prevents venous thromboembolism (VTE), and specific murine models of sepsis have shown potential efficacy in alleviating cytokine storm. These latter findings support the role of FXI beyond coagulation. Here, we combine targeted proteomics, machine learning and bioinformatics, to discover associations between FXI activity (FXI:C) and the plasma protein profile of patients with VTE. FXI:C was measured with a modified activated partial prothrombin time (APTT) clotting time assay. Proximity extension assay-based protein profiling was performed on plasma collected from subjects from the Genotyping and Molecular Phenotyping of Venous Thromboembolism (GMP-VTE) Project, collected during an acute VTE event (n = 549) and 12-months after (n = 187). Among 444 proteins investigated, N = 21 and N = 66 were associated with FXI:C during the acute VTE event and at 12 months follow-up, respectively. Seven proteins were identified as FXI:C-associated at both time points. These FXI-related proteins were enriched in immune pathways related to causes of thrombo-inflammation, extracellular matrix interaction, lipid metabolism, and apoptosis. The results of this study offer important new avenues for future research into the multiple properties of FXI, which are of high clinical interest given the current development of FXI inhibitors., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
34. Variation of platelet function in clinical phenotypes of acute venous thromboembolism - Results from the GMP-VTE project.
- Author
-
Panova-Noeva M, Wagner B, Nagler M, Koeck T, Ten Cate V, Eggebrecht L, Prochaska JH, Meyer I, Gerdes C, Spronk HM, Lackner KJ, Ten Cate H, Leineweber K, Heitmeier S, Konstantinides S, and Wild PS
- Subjects
- Humans, Phenotype, Platelet Function Tests, Pulmonary Embolism diagnosis, Venous Thromboembolism diagnosis, Venous Thromboembolism genetics, Venous Thrombosis diagnosis
- Abstract
Background: The role of platelets in the pathogenesis of venous thromboembolism (VTE) is receiving increasing attention; however, limited information is available on platelet function in the acute phase of the disease., Objective: To characterize platelet function according to VTE phenotypes., Patients/methods: In total, 154 subjects (isolated pulmonary embolism [iPE], n = 28; isolated deep vein thrombosis [iDVT], n = 35; DVT+PE, n = 91) were included. In this study platelet function analyzer (PFA)-200, light transmission aggregometry (LTA), thrombin generation (TG) in presence (PRP) and absence (PFP) of platelets and platelet flow cytometry were investigated. LASSO regression was used to select clinical and platelet biomarkers that distinguish between VTE phenotypes., Results: PFA-200 results did not differ between VTE phenotypes. LTA from DVT+PE subjects showed lowest maximum aggregation after epinephrine and adenosine diphosphate compared to iPE and iDVT. Lower % of PAC-1-positive platelets after in-vitro trigger were present in DVT+PE and iPE compared to iDVT. TG in PRP had lower peak height and velocity in DVT+PE and iPE against iDVT. The results of LASSO regression for the distinction between DVT+PE vs iDVT identified 18 variables (AUC =0.93) of which 72% were platelet biomarkers. For distinction between iPE and iDVT, 10 variables were selected (AUC = 0.96) of which 50% were platelet-related. Obesity was the only variable weakly discriminating between DVT+PE vs iPE (AUC = 0.66)., Conclusion: This explorative study suggests an important distinction between PE-related phenotypes and iDVT when considering clinical and platelet function data. Lower platelet-dependent TG along with reduced platelet reactivity suggest higher platelet degranulation in PE-dependent phenotypes compared to iDVT., (© 2021 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.)
- Published
- 2022
- Full Text
- View/download PDF
35. A targeted proteomics investigation of the obesity paradox in venous thromboembolism.
- Author
-
Ten Cate V, Koeck T, Prochaska J, Schulz A, Panova-Noeva M, Rapp S, Eggebrecht L, Lenz M, Glunz J, Sauer M, Ewert R, Halank M, Münzel T, Heitmeier S, Andrade-Navarro MA, Lackner KJ, Konstantinides SV, Leineweber K, and Wild PS
- Subjects
- Humans, Lectins, C-Type, Matrix Metalloproteinase 2, Membrane Glycoproteins, Obesity complications, Obesity genetics, Prospective Studies, Proteomics, Receptors, Immunologic, Risk Factors, Venous Thromboembolism genetics
- Abstract
The obesity paradox, the controversial finding that obesity promotes disease development but protects against sequelae in patients, has been observed in venous thromboembolism (VTE). The aim of this investigation was to identify a body mass-related proteomic signature in VTE patients and to evaluate whether this signature mediates the obesity paradox in VTE patients. Data from the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism Project, a prospective cohort study of 693 VTE patients, were analyzed. A combined end point of recurrent VTE or all-cause death was used. Relative quantification of 444 proteins was performed using high-throughput targeted proteomics technology. Measurements were performed in samples collected during the acute VTE event and at 12-month follow-up. An 11-protein signature (CLEC4C, FABP4, FLT3LG, IL-17C, LEP, LYVE1, MASP1, ST2, THBS2, THBS4, TSLP) for body mass in VTE patients was identified. The signature did not significantly mediate the obesity paradox (change in hazard ratio [HR]: 0.04; likelihood ratio test of nested models = 7.7; P = .74), but its main constituent protein, leptin, was inversely associated with recurrent VTE or death (adjusted HR [95% confidence interval] per standard deviation increase: 0.66 [0.46-0.94]). This relationship was significantly (P = .007) modified by markers of leptin resistance (ie, high body mass index and high circulating matrix metalloproteinase-2 levels). Although the signature did not substantially explain the obesity paradox, leptin appears to be protective against disease recurrence and death in VTE patients. This protective effect was abrogated under conditions of leptin resistance and hence was unrelated to the obesity paradox., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
36. Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism.
- Author
-
Ten Cate V, Prochaska JH, Schulz A, Koeck T, Pallares Robles A, Lenz M, Eggebrecht L, Rapp S, Panova-Noeva M, Ghofrani HA, Meyer FJ, Espinola-Klein C, Lackner KJ, Michal M, Schuster AK, Strauch K, Zink AM, Laux V, Heitmeier S, Konstantinides SV, Münzel T, Andrade-Navarro MA, Leineweber K, and Wild PS
- Subjects
- Acute-Phase Proteins biosynthesis, Adult, Aged, Atherosclerosis complications, Comorbidity, Datasets as Topic, Female, Follow-Up Studies, Gene Expression Regulation, Glial Cell Line-Derived Neurotrophic Factor biosynthesis, Glial Cell Line-Derived Neurotrophic Factor genetics, Humans, Interferon-gamma biosynthesis, Interferon-gamma genetics, Interleukin-15 Receptor alpha Subunit biosynthesis, Interleukin-15 Receptor alpha Subunit genetics, Machine Learning, Male, Middle Aged, N-Acetylgalactosaminyltransferases biosynthesis, N-Acetylgalactosaminyltransferases genetics, Oxidative Stress, Prospective Studies, Protein Interaction Maps, Protein-Arginine Deiminase Type 2 biosynthesis, Protein-Arginine Deiminase Type 2 genetics, Pulmonary Embolism genetics, Pulmonary Embolism physiopathology, Pulmonary Surfactants, Quantitative Trait Loci, Venous Thromboembolism metabolism, Polypeptide N-acetylgalactosaminyltransferase, Proteome, Pulmonary Embolism metabolism, Transcriptome
- Abstract
Patients with isolated pulmonary embolism (PE) have a distinct clinical profile from those with deep vein thrombosis (DVT)-associated PE, with more pulmonary conditions and atherosclerosis. These findings suggest a distinct molecular pathophysiology and the potential involvement of alternative pathways in isolated PE. To test this hypothesis, data from 532 individuals from the Genotyping and Molecular Phenotyping of Venous ThromboEmbolism Project, a multicenter prospective cohort study with extensive biobanking, were analyzed. Targeted, high-throughput proteomics, machine learning, and bioinformatic methods were applied to contrast the acute-phase plasma proteomes of isolated PE patients (n = 96) against those of patients with DVT-associated PE (n = 276) or isolated DVT (n = 160). This resulted in the identification of shared molecular processes between PE phenotypes, as well as an isolated PE-specific protein signature. Shared processes included upregulation of inflammation, response to oxidative stress, and the loss of pulmonary surfactant. The isolated PE-specific signature consisted of 5 proteins: interferon-γ, glial cell line-derived neurotrophic growth factor, polypeptide N-acetylgalactosaminyltransferase 3, peptidyl arginine deiminase type-2, and interleukin-15 receptor subunit α. These proteins were orthogonally validated using cis protein quantitative trait loci. External replication in an independent population-based cohort (n = 5778) further validated the proteomic results and showed that they were prognostic for incident primary isolated PE in individuals without history of VTE (median time to event: 2.9 years; interquartile range: 1.6-4.2 years), supporting their possible involvement in the early pathogenesis. This study has identified molecular overlaps and differences between VTE phenotypes. In particular, the results implicate noncanonical pathways more commonly associated with respiratory and atherosclerotic disease in the acute pathophysiology of isolated PE., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
37. Missing value imputation in proximity extension assay-based targeted proteomics data.
- Author
-
Lenz M, Schulz A, Koeck T, Rapp S, Nagler M, Sauer M, Eggebrecht L, Ten Cate V, Panova-Noeva M, Prochaska JH, Lackner KJ, Münzel T, Leineweber K, Wild PS, and Andrade-Navarro MA
- Subjects
- Adult, Aged, Algorithms, Bias, Blood Proteins analysis, Blood Proteins standards, Female, Humans, Interleukin-6 blood, Interleukin-6 standards, Limit of Detection, Male, Middle Aged, Multivariate Analysis, Proteomics standards, Quality Control, Venous Thromboembolism metabolism, Venous Thromboembolism pathology, Proteomics methods
- Abstract
Targeted proteomics utilizing antibody-based proximity extension assays provides sensitive and highly specific quantifications of plasma protein levels. Multivariate analysis of this data is hampered by frequent missing values (random or left censored), calling for imputation approaches. While appropriate missing-value imputation methods exist, benchmarks of their performance in targeted proteomics data are lacking. Here, we assessed the performance of two methods for imputation of values missing completely at random, the previously top-benchmarked 'missForest' and the recently published 'GSimp' method. Evaluation was accomplished by comparing imputed with remeasured relative concentrations of 91 inflammation related circulating proteins in 86 samples from a cohort of 645 patients with venous thromboembolism. The median Pearson correlation between imputed and remeasured protein expression values was 69.0% for missForest and 71.6% for GSimp (p = 5.8e-4). Imputation with missForest resulted in stronger reduction of variance compared to GSimp (median relative variance of 25.3% vs. 68.6%, p = 2.4e-16) and undesired larger bias in downstream analyses. Irrespective of the imputation method used, the 91 imputed proteins revealed large variations in imputation accuracy, driven by differences in signal to noise ratio and information overlap between proteins. In summary, GSimp outperformed missForest, while both methods show good overall imputation accuracy with large variations between proteins., Competing Interests: Michael Lenz, Andreas Schulz, Thomas Koeck, Steffen Rapp, Markus Nagler, Lisa Eggebrecht, Vincent Ten Cate, Karl J. Lackner, Thomas Münzel and Miguel A. Andrade-Navarro declare no conflict of interest. Madeleine Sauer and Kirsten Leineweber are employees of Bayer AG. Marina Panova-Noeva, Jürgen H. Prochaska, and Philipp S. Wild received funding from the Center for Thrombosis and Hemostasis Mainz. Philipp S. Wild reports grants from Bayer AG and from the German Federal Ministry of Education and Research, during the conduct of the study; grants and personal fees from Boehringer Ingelheim, grants from Philips Medical Systems, grants and personal fees from Sanofi-Aventis, grants and personal fees from Bayer Vital, grants from Daiichi Sankyo Europe, personal fees from Bayer Health Care, personal fees from Astra Zeneca, personal fees and non-financial support from Diasorin and non-financial support from I.E.M., outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2020
- Full Text
- View/download PDF
38. Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis.
- Author
-
Narula S, Yusuf S, Chong M, Ramasundarahettige C, Rangarajan S, Bangdiwala SI, van Eikels M, Leineweber K, Wu A, Pigeyre M, and Paré G
- Subjects
- Adult, Aged, Angiotensin-Converting Enzyme 2, Body Mass Index, Case-Control Studies, Female, Humans, Male, Middle Aged, Risk Factors, Survival Rate, Cardiovascular Diseases blood, Cardiovascular Diseases mortality, Peptidyl-Dipeptidase A blood
- Abstract
Background: Angiotensin-converting enzyme 2 (ACE2) is an endogenous counter-regulator of the renin-angiotensin hormonal cascade. We assessed whether plasma ACE2 concentrations were associated with greater risk of death or cardiovascular disease events., Methods: We used data from the Prospective Urban Rural Epidemiology (PURE) prospective study to conduct a case-cohort analysis within a subset of PURE participants (from 14 countries across five continents: Africa, Asia, Europe, North America, and South America). We measured plasma concentrations of ACE2 and assessed potential determinants of plasma ACE2 levels as well as the association of ACE2 with cardiovascular events., Findings: We included 10 753 PURE participants in our study. Increased concentration of plasma ACE2 was associated with increased risk of total deaths (hazard ratio [HR] 1·35 per 1 SD increase [95% CI 1·29-1·43]) with similar increases in cardiovascular and non-cardiovascular deaths. Plasma ACE2 concentration was also associated with higher risk of incident heart failure (HR 1·27 per 1 SD increase [1·10-1·46]), myocardial infarction (HR 1·23 per 1 SD increase [1·13-1·33]), stroke (HR 1·21 per 1 SD increase [1·10-1·32]) and diabetes (HR 1·44 per 1 SD increase [1·36-1·52]). These findings were independent of age, sex, ancestry, and traditional cardiac risk factors. With the exception of incident heart failure events, the independent relationship of ACE2 with the clinical endpoints, including death, remained robust after adjustment for BNP. The highest-ranked determinants of ACE2 concentrations were sex, geographic ancestry, and body-mass index (BMI). When compared with clinical risk factors (smoking, diabetes, blood pressure, lipids, and BMI), ACE2 was the highest ranked predictor of death, and superseded several risk factors as a predictor of heart failure, stroke, and myocardial infarction., Interpretation: Increased plasma ACE2 concentration was associated with increased risk of major cardiovascular events in a global study., Funding: Canadian Institute of Health Research, Heart & Stroke Foundation of Canada, and Bayer., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
39. Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism - results from clinical observation studies.
- Author
-
Panova-Noeva M, Wagner B, Nagler M, Koeck T, Ten Cate V, Prochaska JH, Heitmeier S, Meyer I, Gerdes C, Laux V, Konstantinides S, Spronk HM, Münzel T, Lackner KJ, Leineweber K, Ten Cate H, and Wild PS
- Subjects
- Acute Disease, Aged, Biomarkers, Female, Humans, Immunophenotyping, Machine Learning, Male, Middle Aged, Platelet Activation, Platelet Aggregation, Platelet Count, Platelet Function Tests, Risk Factors, Thrombin biosynthesis, Venous Thromboembolism diagnosis, Blood Platelets metabolism, Disease Susceptibility, Venous Thromboembolism etiology, Venous Thromboembolism metabolism
- Abstract
Background: The pathogenesis of arterial and venous thrombosis is in large part interlaced. How much platelet phenotype relates to acute venous thromboembolism (VTE) independent of the underlying cardiovascular profile is presently poorly investigated., Methods: Platelet count and mean platelet volume (MPV), platelet aggregation in whole blood and platelet rich plasma (PRP), platelet-dependent thrombin generation (TG) and platelet surface activation markers were measured under standardized conditions. Machine learning was applied to identify the most relevant characteristics associated with VTE from a large array (N = 58) of clinical and platelet-related variables., Findings: VTE cases (N = 159) presented with lower platelet count and MPV vs controls (N = 140). Whole blood aggregation showed shorter collagen/Epinephrine closure times in cases, particularly within acetylsalicylic acid (ASA) users. Within ASA users, higher PRP aggregation after adenosine diphosphate (ADP), epinephrine, collagen and arachidonic acid was observed in cases vs controls. Within non-ASA and/or subjects on anticoagulants, cases presented with lower aggregation after ADP and collagen vs controls. Lower platelet-dependent TG, higher CD63 on resting and lower PAC-1 expression after collagen/ADP in-vitro stimulated platelets further characterized VTE cases vs controls, independent of therapy. Lasso regression analysis identified 26 variables associated with VTE of which 69% were platelet-related., Interpretation: Comprehensive phenotyping of platelet function identified a large proportion of low responders to ASA in VTE cases. Lower platelet-dependent TG and lower platelet reactivity after ex-vivo stimulation characterized the "platelet exhausted syndrome" in cases. Finally, from a large array of covariates including clinical risk factors, platelet biomarkers comprised 69% of all selected variables differentiating VTE cases vs controls., Funding: German Federal Ministry of Education and Research, CTH-Mainz and Bayer AG., (Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
40. ADTRP regulates TFPI expression via transcription factor POU1F1 involved in coronary artery disease.
- Author
-
Luo C, Pook E, Wang F, Archacki SR, Tang B, Zhang W, Hu JS, Yang J, Leineweber K, Bechem M, Huang W, Song Y, Cheung SH, Laux V, Ke T, Ren X, Tu X, Chen Q, Wang QK, and Xu C
- Subjects
- Atherosclerosis genetics, Case-Control Studies, Cell Line, Chromatin Immunoprecipitation methods, Coronary Artery Disease genetics, Databases, Genetic, Endothelial Cells metabolism, Genes, Homeobox, HeLa Cells, Humans, Lipoproteins genetics, Lipoproteins metabolism, Membrane Proteins genetics, Membrane Proteins physiology, Promoter Regions, Genetic, Response Elements, Transcription Initiation Site, Transcription, Genetic, Coronary Artery Disease metabolism, Lipoproteins biosynthesis, Membrane Proteins metabolism, Transcription Factor Pit-1 metabolism
- Abstract
Genomic variants in both ADTRP and TFPI genes are associated with risk of coronary artery disease (CAD). ADTRP regulates TFPI expression and endothelial cell functions involved in the initiation of atherosclerotic CAD. ADTRP also specifies primitive myelopoiesis and definitive hematopoiesis by upregulating TFPI expression. However, the underlying molecular mechanism is unknown. Here we show that transcription factor POU1F1 is the key by which ADTRP regulates TFPI expression. Luciferase reporter assays, chromatin-immunoprecipitation (ChIP) and electrophoretic mobility shift assay (EMSA) in combination with analysis of large and small deletions of the TFPI promoter/regulatory region were used to identify the molecular mechanism by which ADTRP regulates TFPI expression. Genetic association was assessed using case-control association analysis and phenome-wide association analysis (PhenGWA). ADTRP regulates TFPI expression at the transcription level in a dose-dependent manner. The ADTRP-response element was localized to a 50 bp region between -806 bp and -756 bp upstream of TFPI transcription start site, which contains a binding site for POU1F1. Deletion of POU1F1-binding site or knockdown of POU1F1 expression abolished ADTRP-mediated transcription of TFPI. ChIP and EMSA demonstrated that POU1F1 binds to the ADTRP response element. Genetic analysis identified significant association between POU1F1 variants and risk of CAD. PhenGWA identified other phenotypic traits associated with the ADTRP-POU1F1-TFPI axis such as lymphocyte count (ADTRP), waist circumference (TFPI), and standing height (POU1F1). These data identify POU1F1 as a transcription factor that regulates TFPI transcription in response to ADTRP, and link POU1F1 variants to risk of CAD for the first time., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
41. Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart.
- Author
-
Fender AC, Kleeschulte S, Stolte S, Leineweber K, Kamler M, Bode J, Li N, and Dobrev D
- Subjects
- Aged, Animals, Caspase 1 metabolism, Cells, Cultured, Diabetes Mellitus etiology, Diabetes Mellitus genetics, Diabetes Mellitus immunology, Diabetic Cardiomyopathies etiology, Diabetic Cardiomyopathies genetics, Diabetic Cardiomyopathies immunology, Diet, High-Fat, Disease Models, Animal, Female, Fibroblasts immunology, Fibroblasts metabolism, Humans, Inflammasomes immunology, Interleukin-1beta metabolism, Intracellular Signaling Peptides and Proteins metabolism, Male, Mice, Inbred C57BL, Mice, Knockout, Middle Aged, Myocardium immunology, Phosphate-Binding Proteins metabolism, Receptors, Thrombin deficiency, Receptors, Thrombin genetics, Signal Transduction, Diabetes Mellitus metabolism, Diabetic Cardiomyopathies metabolism, Inflammasomes metabolism, Myocardium metabolism, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Receptors, Thrombin metabolism
- Abstract
The deleterious effects of diabetes in the heart are increasingly attributed to inflammatory signaling through the NLRP3 (NOD, LRR and PYD domains-containing protein 3) inflammasome. Thrombin antagonists reduce cardiac remodeling and dysfunction in diabetic mice, in part by suppressing fibrin-driven inflammation. The role of cellular thrombin receptor subtypes in this context is not known. We sought to determine the causal involvement of protease-activated receptors (PAR) in inflammatory signaling of the diabetic heart. Mice with diet-induced diabetes showed increased abundance of pro-caspase-1 and pro-interleukin (IL)-1β in the left ventricle (LV), indicating transcriptional NLRP3 inflammasome priming, and augmented cleavage of active caspase-1 and IL-1β, pointing to canonical NLRP3 inflammasome activation. Caspase-11 activation, which mediates non-canonical NLRP3 inflammasome signaling, was not augmented. Formation of the plasma membrane pore-forming protein N-terminal gasdermin D (GDSMD), a prerequisite for IL-1β secretion, was also higher in diabetic vs. control mouse LV. NLRP3, ASC and IL-18 expression did not differ between the groups, nor did expression of PAR1 or PAR2. PAR3 was nearly undetectable. LV abundance of PAR4 by contrast increased with diabetes and correlated positively with active caspase-1. Genetic deletion of PAR4 in mice prevented the diet-induced cleavage of caspase-1, IL-1β and GDSMD. Right atrial appendages from patients with type 2 diabetes also showed higher levels of PAR4, but not of PAR1 or PAR2, than non-diabetic atrial tissue, along with increased abundance of cleaved caspase-1, IL-1β and GSDMD. Human cardiac fibroblasts maintained in high glucose conditions to mimic diabetes also upregulated PAR4 mRNA and protein, and increased PAR4-dependent IL-1β transcription and secretion in response to thrombin, while PAR1 and PAR2 expressions were unaltered. In conclusion, PAR4 drives caspase-1-dependent IL-1β production through the canonical NLRP3 inflammasome pathway in the diabetic heart, providing mechanistic insights into diabetes-associated cardiac thromboinflammation. The emerging PAR4-selective antagonists may provide a feasible approach to prevent cardiac inflammation in patients with diabetes.
- Published
- 2020
- Full Text
- View/download PDF
42. Heart failure with preserved ejection fraction in Asia.
- Author
-
Tromp J, Teng TH, Tay WT, Hung CL, Narasimhan C, Shimizu W, Park SW, Liew HB, Ngarmukos T, Reyes EB, Siswanto BB, Yu CM, Zhang S, Yap J, MacDonald M, Ling LH, Leineweber K, Richards AM, Zile MR, Anand IS, and Lam CSP
- Subjects
- Aged, Asia epidemiology, Comorbidity, Echocardiography, Female, Follow-Up Studies, Heart Failure diagnosis, Heart Failure physiopathology, Humans, Male, Middle Aged, Prevalence, Prospective Studies, Ventricular Function, Left, Heart Failure epidemiology, Public Health, Stroke Volume physiology
- Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem. Unfortunately, little is known about HFpEF across Asia., Methods and Results: We prospectively studied clinical characteristics, echocardiographic parameters and outcomes in 1204 patients with HFpEF (left ventricular ejection fraction ≥50%) from 11 Asian regions, grouped as Northeast Asia (Hong Kong, Taiwan, China, Japan, Korea, n = 543), South Asia (India, n = 252), and Southeast Asia (Malaysia, Thailand, Singapore, Indonesia, Philippines, n = 409). Mean age was 68 ±12 years (37% were < 65 years) and 50% were women. Seventy per cent of patients had ≥2 co-morbidities, most commonly hypertension (71%), followed by anaemia (57%), chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%) and obesity (26%). Southeast Asian patients had the highest prevalence of all co-morbidities except atrial fibrillation, South Asians had the lowest prevalence of all co-morbidities except anaemia and obesity, and Northeast Asians had more atrial fibrillation. Left ventricular hypertrophy and concentric remodelling were most prominent among Southeast and South Asians, respectively (P < 0.001). Overall, 12.1% of patients died or were hospitalized for heart failure within 1 year. Southeast Asians were at higher risk for adverse outcomes, independent of co-morbidity burden and cardiac geometry., Conclusion: These first prospective multinational data from Asia show that HFpEF affects relatively young patients with a high burden of co-morbidities. Regional differences in types of co-morbidities, cardiac remodelling and outcomes of HFpEF across Asia have important implications for public health measures and global HFpEF trial design., (© 2018 The Authors. European Journal of Heart Failure & 2018 European Society of Cardiology.)
- Published
- 2019
- Full Text
- View/download PDF
43. Multi-ethnic genome-wide association study for atrial fibrillation.
- Author
-
Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, Almgren P, Alonso A, Anderson CD, Aragam KG, Arking DE, Barnard J, Bartz TM, Benjamin EJ, Bihlmeyer NA, Bis JC, Bloom HL, Boerwinkle E, Bottinger EB, Brody JA, Calkins H, Campbell A, Cappola TP, Carlquist J, Chasman DI, Chen LY, Chen YI, Choi EK, Choi SH, Christophersen IE, Chung MK, Cole JW, Conen D, Cook J, Crijns HJ, Cutler MJ, Damrauer SM, Daniels BR, Darbar D, Delgado G, Denny JC, Dichgans M, Dörr M, Dudink EA, Dudley SC, Esa N, Esko T, Eskola M, Fatkin D, Felix SB, Ford I, Franco OH, Geelhoed B, Grewal RP, Gudnason V, Guo X, Gupta N, Gustafsson S, Gutmann R, Hamsten A, Harris TB, Hayward C, Heckbert SR, Hernesniemi J, Hocking LJ, Hofman A, Horimoto ARVR, Huang J, Huang PL, Huffman J, Ingelsson E, Ipek EG, Ito K, Jimenez-Conde J, Johnson R, Jukema JW, Kääb S, Kähönen M, Kamatani Y, Kane JP, Kastrati A, Kathiresan S, Katschnig-Winter P, Kavousi M, Kessler T, Kietselaer BL, Kirchhof P, Kleber ME, Knight S, Krieger JE, Kubo M, Launer LJ, Laurikka J, Lehtimäki T, Leineweber K, Lemaitre RN, Li M, Lim HE, Lin HJ, Lin H, Lind L, Lindgren CM, Lokki ML, London B, Loos RJF, Low SK, Lu Y, Lyytikäinen LP, Macfarlane PW, Magnusson PK, Mahajan A, Malik R, Mansur AJ, Marcus GM, Margolin L, Margulies KB, März W, McManus DD, Melander O, Mohanty S, Montgomery JA, Morley MP, Morris AP, Müller-Nurasyid M, Natale A, Nazarian S, Neumann B, Newton-Cheh C, Niemeijer MN, Nikus K, Nilsson P, Noordam R, Oellers H, Olesen MS, Orho-Melander M, Padmanabhan S, Pak HN, Paré G, Pedersen NL, Pera J, Pereira A, Porteous D, Psaty BM, Pulit SL, Pullinger CR, Rader DJ, Refsgaard L, Ribasés M, Ridker PM, Rienstra M, Risch L, Roden DM, Rosand J, Rosenberg MA, Rost N, Rotter JI, Saba S, Sandhu RK, Schnabel RB, Schramm K, Schunkert H, Schurman C, Scott SA, Seppälä I, Shaffer C, Shah S, Shalaby AA, Shim J, Shoemaker MB, Siland JE, Sinisalo J, Sinner MF, Slowik A, Smith AV, Smith BH, Smith JG, Smith JD, Smith NL, Soliman EZ, Sotoodehnia N, Stricker BH, Sun A, Sun H, Svendsen JH, Tanaka T, Tanriverdi K, Taylor KD, Teder-Laving M, Teumer A, Thériault S, Trompet S, Tucker NR, Tveit A, Uitterlinden AG, Van Der Harst P, Van Gelder IC, Van Wagoner DR, Verweij N, Vlachopoulou E, Völker U, Wang B, Weeke PE, Weijs B, Weiss R, Weiss S, Wells QS, Wiggins KL, Wong JA, Woo D, Worrall BB, Yang PS, Yao J, Yoneda ZT, Zeller T, Zeng L, Lubitz SA, Lunetta KL, and Ellinor PT
- Subjects
- Atrial Fibrillation ethnology, Case-Control Studies, Genetic Predisposition to Disease, Genome-Wide Association Study methods, Humans, Quantitative Trait Loci, Transcriptome, Atrial Fibrillation genetics, Ethnicity genetics
- Abstract
Atrial fibrillation (AF) affects more than 33 million individuals worldwide
1 and has a complex heritability2 . We conducted the largest meta-analysis of genome-wide association studies (GWAS) for AF to date, consisting of more than half a million individuals, including 65,446 with AF. In total, we identified 97 loci significantly associated with AF, including 67 that were novel in a combined-ancestry analysis, and 3 that were novel in a European-specific analysis. We sought to identify AF-associated genes at the GWAS loci by performing RNA-sequencing and expression quantitative trait locus analyses in 101 left atrial samples, the most relevant tissue for AF. We also performed transcriptome-wide analyses that identified 57 AF-associated genes, 42 of which overlap with GWAS loci. The identified loci implicate genes enriched within cardiac developmental, electrophysiological, contractile and structural pathways. These results extend our understanding of the biological pathways underlying AF and may facilitate the development of therapeutics for AF.- Published
- 2018
- Full Text
- View/download PDF
44. Correction: Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry.
- Author
-
Tromp J, Tay WT, Ouwerkerk W, Teng TK, Yap J, MacDonald MR, Leineweber K, McMurray JJV, Zile MR, Anand IS, Richards AM, and Lam CSP
- Abstract
[This corrects the article DOI: 10.1371/journal.pmed.1002541.].
- Published
- 2018
- Full Text
- View/download PDF
45. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry.
- Author
-
Tromp J, Tay WT, Ouwerkerk W, Teng TK, Yap J, MacDonald MR, Leineweber K, McMurray JJV, Zile MR, Anand IS, Richards AMR, and Lam CSP
- Subjects
- Aged, Aged, 80 and over, Asia epidemiology, Asian People, Atrial Fibrillation complications, Comorbidity, Diabetes Complications epidemiology, Female, Geography, Humans, Hypertension complications, Hypertension epidemiology, Kaplan-Meier Estimate, Latent Class Analysis, Male, Middle Aged, Obesity complications, Obesity epidemiology, Phenotype, Prospective Studies, Quality of Life, Registries, Severity of Illness Index, Surveys and Questionnaires, Heart Failure complications, Heart Failure epidemiology, Multimorbidity
- Abstract
Background: Comorbidities are common in patients with heart failure (HF) and complicate treatment and outcomes. We identified patterns of multimorbidity in Asian patients with HF and their association with patients' quality of life (QoL) and health outcomes., Methods and Findings: We used data on 6,480 patients with chronic HF (1,204 with preserved ejection fraction) enrolled between 1 October 2012 and 6 October 2016 in the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. The ASIAN-HF registry is a prospective cohort study, with patients prospectively enrolled from in- and outpatient clinics from 11 Asian regions (Hong Kong, Taiwan, China, Japan, Korea, India, Malaysia, Thailand, Singapore, Indonesia, and Philippines). Latent class analysis was used to identify patterns of multimorbidity. The primary outcome was defined as a composite of all-cause mortality or HF hospitalization within 1 year. To assess differences in QoL, we used the Kansas City Cardiomyopathy Questionnaire. We identified 5 distinct multimorbidity groups: elderly/atrial fibrillation (AF) (N = 1,048; oldest, more AF), metabolic (N = 1,129; obesity, diabetes, hypertension), young (N = 1,759; youngest, low comorbidity rates, non-ischemic etiology), ischemic (N = 1,261; ischemic etiology), and lean diabetic (N = 1,283; diabetic, hypertensive, low prevalence of obesity, high prevalence of chronic kidney disease). Patients in the lean diabetic group had the worst QoL, more severe signs and symptoms of HF, and the highest rate of the primary combined outcome within 1 year (29% versus 11% in the young group) (p for all <0.001). Adjusting for confounders (demographics, New York Heart Association class, and medication) the lean diabetic (hazard ratio [HR] 1.79, 95% CI 1.46-2.22), elderly/AF (HR 1.57, 95% CI 1.26-1.96), ischemic (HR 1.51, 95% CI 1.22-1.88), and metabolic (HR 1.28, 95% CI 1.02-1.60) groups had higher rates of the primary combined outcome compared to the young group. Potential limitations include site selection and participation bias., Conclusions: Among Asian patients with HF, comorbidities naturally clustered in 5 distinct patterns, each differentially impacting patients' QoL and health outcomes. These data underscore the importance of studying multimorbidity in HF and the need for more comprehensive approaches in phenotyping patients with HF and multimorbidity., Trial Registration: ClinicalTrials.gov NCT01633398.
- Published
- 2018
- Full Text
- View/download PDF
46. Genetics of NO Deficiency.
- Author
-
Leineweber K, Moosmang S, and Paulson D
- Subjects
- Cyclic GMP physiology, Humans, Signal Transduction, Cardiovascular Diseases etiology, Nitric Oxide deficiency, Nitric Oxide genetics
- Abstract
The nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway plays a key role in regulating cardiovascular homeostasis, and genetic variants allocated to NO-cGMP pathway genes, leading to NO-cGMP deficiency, may influence the prevalence or course of cardiovascular disease. NO-cGMP deficiency can be caused by nitric oxide synthase substrate deficiency, substrate competition, defects, or uncoupling; endogenous inhibitors of nitric oxide synthase; decreased cGMP production; or increased cGMP degradation. This review presents evidence supporting the role of NO-cGMP deficiency in cardiovascular disease, including findings from genetic association studies for particular polymorphisms, haplotypes, and racial disparities. NO-cGMP pathway components including arginases, guanosine-5'-triphosphate cyclohydrolase 1, nitric oxide synthase, dimethylarginine dimethylaminohydrolases, soluble guanylyl cyclase, protein kinase G, phosphodiesterase 5, and natriuretic peptides will be discussed., (Copyright © 2017. Published by Elsevier Inc.)
- Published
- 2017
- Full Text
- View/download PDF
47. Androgen inhibits key atherosclerotic processes by directly activating ADTRP transcription.
- Author
-
Luo C, Pook E, Tang B, Zhang W, Li S, Leineweber K, Cheung SH, Chen Q, Bechem M, Hu JS, Laux V, and Wang QK
- Subjects
- Atherosclerosis genetics, Atherosclerosis pathology, Coculture Techniques, Coronary Artery Disease genetics, Coronary Artery Disease pathology, Endothelial Cells metabolism, Genome-Wide Association Study, HL-60 Cells, HeLa Cells, Humans, Membrane Proteins genetics, Monocytes metabolism, Monocytes pathology, Transendothelial and Transepithelial Migration drug effects, Androgens pharmacology, Atherosclerosis metabolism, Coronary Artery Disease metabolism, Gene Expression Regulation drug effects, Membrane Proteins biosynthesis, Response Elements, Transcription, Genetic drug effects
- Abstract
Low androgen levels are associated with an increased risk of coronary artery disease (CAD), thrombosis and myocardial infarction (MI), suggesting that androgen has a protective role. However, little is known about the underlying molecular mechanism. Our genome-wide association study identified the ADTRP gene encoding the androgen-dependent TFPI regulating protein as a susceptibility gene for CAD and MI. The expression level of ADTRP was regulated by androgen, but the molecular mechanism is unknown. In this study, we identified the molecular mechanism by which androgen regulates ADTRP expression and tested the hypothesis that androgen plays a protective role in cardiovascular disease by activating ADTRP expression. Luciferase assays with an ADTRP promoter luciferase reporter revealed that androgen regulated ADTRP transcription in a dose- and time-dependent manner, and the effect was abolished by three different androgen inhibitors, including pyrvinium pamoate, bicalutamide, and cyproterone acetate. Chromatin-immunoprecipitation showed that the androgen receptor bound to a half androgen response element (ARE, TGTTCT) located at +324bp from the ADTRP transcription start site. The ARE is required for concentration-dependent transcriptional activation of ADTRP. HL-60 monocyte adhesion to EAhy926 endothelial cells (ECs) and transmigration across the EC layer, the two processes critical to development of CAD and MI, were inhibited by androgen, but the effect was rescued by ADTRP siRNA and exacerbated by overexpression of ADTRP and its downstream genes PIK3R3 and MIA3. These data suggest that one molecular mechanism by which androgen confers protection against CAD is stimulation of ADTRP expression., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
48. Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction.
- Author
-
Primessnig U, Schönleitner P, Höll A, Pfeiffer S, Bracic T, Rau T, Kapl M, Stojakovic T, Glasnov T, Leineweber K, Wakula P, Antoons G, Pieske B, and Heinzel FR
- Subjects
- Animals, Caffeine pharmacology, Calcium metabolism, Central Nervous System Stimulants pharmacology, Echocardiography, Heart Failure complications, Heart Failure diagnostic imaging, Hypertrophy, Left Ventricular complications, Hypertrophy, Left Ventricular diagnostic imaging, Hypertrophy, Left Ventricular physiopathology, Male, Myocytes, Cardiac metabolism, Myocytes, Cardiac physiology, Rats, Rats, Wistar, Renal Insufficiency, Chronic complications, Aniline Compounds pharmacology, Heart Failure physiopathology, Myocytes, Cardiac drug effects, Phenyl Ethers pharmacology, Renal Insufficiency, Chronic physiopathology, Sodium-Calcium Exchanger antagonists & inhibitors, Stroke Volume
- Abstract
Aims: Heart failure with preserved ejection fraction (HFpEF) is increasingly common, but the underlying cellular mechanisms are not well understood. We investigated cardiomyocyte function and the role of SEA0400, an Na(+) /Ca(2+) exchanger (NCX) inhibitor in a rat model of chronic kidney disease (CKD) with HFpEF., Methods and Results: Male Wistar rats were subjected to subtotal nephrectomy (NXT) or sham operation (Sham). After 8 and 24 weeks, in vivo (haemodynamics, echocardiography) and in vitro function (LV cardiomyocyte cell shortening (CS), and Ca(2+) transients (CaT)) were determined without and with SEA0400. In a subgroup of rats, SEA0400 or vehicle was given p.o. (1 mg/kg b.w.) between week 8 and 24. NXT resulted in stable compensated CKD and HFpEF [hypertrophied left ventricle, prolonged LV isovolumetric relaxation constant TAU (IVRc TAU), elevated end diastolic pressure (EDP), increased lung weight (pulmonary congestion), and preserved LV systolic function (EF, dP/dt)]. In NXT cardiomyocytes, the amplitude of CS and CaT were unchanged but relaxation and CaT decay were progressively prolonged at 8 and 24 weeks vs. Sham, individually correlating with diastolic dysfunction in vivo. NCX forward mode activity (caffeine response) was progressively reduced, while NCX protein expression was up-regulated, suggesting increased NCX reverse mode activity in NXT. SEA0400 acutely improved relaxation in NXT in vivo and in cardiomyocytes and improved cardiac remodelling and diastolic function when given chronically., Conclusions: This model of renal HFpEF is associated with slowed relaxation of LV cardiomyocytes. Treatment with SEA0400 improved cardiomyocyte function, remodelling, and HFpEF., (© 2016 The Authors. European Journal of Heart Failure © 2016 European Society of Cardiology.)
- Published
- 2016
- Full Text
- View/download PDF
49. Coronary atherosclerosis burden, but not transient troponin elevation, predicts long-term outcome in recreational marathon runners.
- Author
-
Möhlenkamp S, Leineweber K, Lehmann N, Braun S, Roggenbuck U, Perrey M, Broecker-Preuss M, Budde T, Halle M, Mann K, Jöckel KH, Erbel R, and Heusch G
- Subjects
- Aged, Coronary Artery Disease mortality, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction epidemiology, Myocardial Infarction mortality, Prognosis, Proportional Hazards Models, Risk Factors, Running, Time Factors, Athletes, Coronary Artery Disease epidemiology, Troponin blood
- Abstract
We determined the prognostic value of transient increases in high-sensitive serum troponin I (hsTnI) during a marathon and its association with traditional cardiovascular risk factors and imaging-based risk markers for incident coronary events and all-cause mortality in recreational marathon runners. Baseline data of 108 marathon runners, 864 age-matched controls and 216 age- and risk factor-matched controls from the general population were recorded and their coronary event rates and all-cause mortality after 6 ± 1 years determined. hsTnI was measured in 74 marathon finishers before and after the race. Other potential predictors for coronary events, i.e., Framingham Risk Score (FRS), coronary artery calcium (CAC) and presence of myocardial fibrosis as measured by magnetic resonance imaging-based late gadolinium enhancement (LGE), were also assessed. An increase beyond the 99 % hsTnI-threshold, i.e., 0.04 μg/L, was observed in 36.5 % of runners. FRS, CAC, or prevalent LGE did not predict hsTnI values above or increases in hsTnI beyond the median after the race, nor did they predict future events. However, runners with versus without LGE had higher hsTnI values after the race (median (Q1/Q3), 0.08 μg/L (0.04/0.09) versus 0.03 μg/L (0.02/0.06), p = 0.039), and higher increases in hsTnI values during the race (median (Q1/Q3), 0.05 μg/L (0.03/0.08) versus 0.02 μg/L (0.01/0.05), p = 0.0496). Runners had a similar cumulative event rate as age-matched or age- and risk factor-matched controls, i.e., 6.5 versus 5.0 % or 4.6 %, respectively. Event rates in runners with CAC scores <100, 100-399, and ≥400 were 1.5, 12.0, and 21.4 % (p = 0.002 for trend) and not different from either control group. Runners with coronary events had a higher prevalence of LGE than runners without events (57 versus 8 %, p = 0.003). All-cause mortality was similar in marathon runners (3/108, 2.8 %) and controls (26/864, 3.0 % or 5/216, 2.4 %, respectively). Recreational marathon runners with prevalent myocardial fibrosis develop higher hsTnI values during the race than those without. Increasing coronary artery calcium scores and prevalent myocardial fibrosis, but not increases in hsTnI are associated with higher coronary event rates. All-cause mortality in marathon runners is similar to that in risk factor-matched controls.
- Published
- 2014
- Full Text
- View/download PDF
50. Mechanical load-dependent cardiac ER stress in vitro and in vivo: effects of preload and afterload.
- Author
-
Toischer K, Kochhäuser S, Nguyen van P, Leineweber K, Hasenfuss G, and Kögler H
- Subjects
- Angiotensin II metabolism, Animals, Biomechanical Phenomena, Endoplasmic Reticulum Chaperone BiP, Female, Male, Mice, Monocrotaline pharmacology, Myocardium metabolism, Pressure, Rabbits, Rats, Time Factors, Endoplasmic Reticulum Stress drug effects, Myocardium cytology, Stress, Mechanical
- Abstract
Proteins are folded in the endoplasmic reticulum (ER). ER stress initially leads to compensatory upregulation of ER chaperones and later to apoptosis, but the contribution of biomechanical load vs. neurohumoral stress to myocardial ER stress is unknown. We show that the ER chaperones Grp78 and calreticulin (CRT) are upregulated by afterload, but not by preload in vitro and in vivo. Angiotensin II upregulated ER chaperones in unloaded muscle strips, but the angiotensin receptor-1 antagonist irbesartan did not significantly blunt the induction of ER chaperones by afterload. In monocrotaline-treated rats, Grp78 and CRT were upregulated in the afterloaded right ventricle, but not in the only neurohumorally stressed left ventricle. These findings suggest that afterload but not preload induces myocardial ER stress, largely independent of angiotensin II signaling., (Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.